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ABSTRACT
Introduction: Malignant pleural effusion can
complicate most cancers. It causes breathlessness and
requires hospitalisation for invasive pleural drainages.
Malignant effusions often herald advanced cancers and
limited prognosis. Minimising time spent in hospital is
of high priority to patients and their families. Various
treatment strategies exist for the management of
malignant effusions, though there is no consensus
governing the best choice. Talc pleurodesis is the
conventional management but requires hospitalisation
(and substantial healthcare resources), can cause
significant side effects, and has a suboptimal success
rate. Indwelling pleural catheters (IPCs) allow
ambulatory fluid drainage without hospitalisation, and
are increasingly employed for management of
malignant effusions. Previous studies have only
investigated the length of hospital care immediately
related to IPC insertion. Whether IPC management
reduces time spent in hospital in the patients’
remaining lifespan is unknown. A strategy of malignant
effusion management that reduces hospital admission
days will allow patients to spend more time outside
hospital, reduce costs and save healthcare resources.
Methods and analysis: The Australasian Malignant
Pleural Effusion (AMPLE) trial is a multicentred,
randomised trial designed to compare IPC with talc
pleurodesis for the management of malignant pleural
effusion. This study will randomise 146 adults with
malignant pleural effusions (1:1) to IPC management
or talc slurry pleurodesis. The primary end point is the
total number of days spent in hospital (for any
admissions) from treatment procedure to death or end
of study follow-up. Secondary end points include
hospital days specific to pleural effusion management,
adverse events, self-reported symptom and quality-of-
life scores.
Ethics and dissemination: The Sir Charles Gairdner
Group Human Research Ethics Committee has
approved the study as have the ethics boards of all the
participating hospitals. The trial results will be
published in peer-reviewed journals and presented at
scientific conferences.
Trial registration numbers: Australia New Zealand
Clinical Trials Registry—ACTRN12611000567921;
National Institutes of Health—NCT02045121.
Malignant pleural effusion is common and can
complicate most cancers, including one-third
of patients with lung and breast carcinomas1 2
and most (>90%) patients with malignant
pleural mesothelioma.3 Malignant pleural effu-
sions cause breathlessness and frequently
require hospitalisation for invasive pleural
drainage procedures. In Western Australia
(population 1.8 million) alone, inpatient care
cost for malignant pleural effusions is estimated
to exceed US$12 million per year.
Strengths and limitations of this study
▪ Multicentre, randomised trial of indwelling
pleural catheter versus talc pleurodesis in malig-
nant pleural effusion.
▪ The study compares the effects of intervention
on total days patients spent in hospital, from any
causes, until death or end of study follow-up—a
meaningful and important end point for patients
with advanced cancers, which has not been
studied before.
▪ The study includes centres from Australia, New
Zealand, Singapore and Hong Kong.
▪ Evaluation of the relative merits of IPC versus
talc slurry pleurodesis in pragmatic, ‘real life’,
clinical environments.
▪ Patients with a malignant pleural effusion are a
diverse group with a wide range of underlying
cancers, demographics, comorbidity and
prognosis.
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Malignant effusions often herald advanced cancers
and limited prognosis. The average life expectancy for
patients with this condition is 3 (for metastatic carcin-
omas) to 9 months (for mesothelioma). Minimising days
spent in hospital to maximise time spent at home and/
or with family is a high priority to patients.4 5 The ideal
treatment approach should include effective long-term
symptoms relief (especially dyspnoea), minimal hospital-
isation and have the least adverse effects.6 Conventional
management involves inpatient talc pleurodesis, which
requires hospitalisation, often of 4–6 days in reported
series.7 8
Talc pleurodesis also has a high failure rate, which
necessitates further pleural interventions/drainages and
hospital care. A randomised trial of 482 patients with
malignant pleural effusions showed that talc pleurodesis,
irrespective of whether delivered by thoracoscopic poud-
rage or talc slurry via tube thoracostomy, successfully
controlled ﬂuid recurrence in only ∼75% of patients at
1 month, and 50% by 6 months.9 Our recent study of
pleurodesis in patients with mesothelioma also showed
that 71% had ﬂuid recurrence, and 32% required
further pleural interventions.10
Talc pleurodesis is known also to have signiﬁcant side
effects.11 Pain and fever are common, and transient hyp-
oxaemia in the several days following pleurodesis days
has been reported. It is now recognised that pleurodesis
with non-graded talc (still the only type of talc prepar-
ation available in many countries) can result in acute
respiratory distress syndrome.12 In the study of Dresler
et al,9 5.3% of 419 evaluable patients developed respira-
tory failure with a mortality rate of 2%.
Indwelling pleural catheters (IPCs) allow ambulatory
ﬂuid drainage and are free from side effects, the need
for hospitalisation and costs of pleurodesis.13 IPC is
increasingly employed for the management of malignant
effusions.14 15 To date, two randomised studies have
compared IPC with talc pleurodesis,7 16 and another
with doxycycline pleurodesis.8 Davies et al7 randomised
106 patients with malignant effusions and showed that
IPC offered equally good symptom relief (dyspnoea and
quality-of-life scores were the key end points) compared
with talc pleurodesis. Putnam et al8 randomised 144
patients and also found similar symptomatic beneﬁts
between IPC and doxycycline pleurodesis. Patients
undergoing pleurodesis spend longer times in hospital
for the initial procedure (median 4 vs 0 days as reported
by Davies et al7 and 6.5 vs 1.0 days by Putnam et al8).
Whether the use of IPC or pleurodesis impacts on the
subsequent need for hospitalisation in the patient’s
remaining lifespan has not been deﬁned. Four compari-
sons of pleurodesis and IPC all found that patients
undergoing pleurodesis were more likely to need subse-
quent pleural drainage procedures with a pooled failure
rate of 22.1% (36/163), compared with 8.9% in IPC
patients (21/236).7 8 17 18 On the other hand, IPC
requires ongoing care and is known to have a different
set of complications19 (eg, infection,20 blockage,
symptomatic loculations, catheter track metastases,21
etc) which could trigger hospital care.
In a pilot, non-randomised patient-choice study, we
found in 65 patients with malignant effusions that those
who elected to have IPC management spent fewer days
in hospital in their remaining lifespan in pleural-related
as well as all-cause hospital stay compared with those
treated with talc pleurodesis.17 The pleurodesis group
spent 11.2% of their remaining life in hospital as
opposed to 8.0% for the group with IPC (p<0.001). The
AMPLE (Australasian Malignant Pleural Effusion) trial is
designed to further evaluate the ﬁndings in a multi-
centred and randomised setting.
METHODS AND ANALYSIS
The AMPLE trial is a multicentred, prospective, rando-
mised trial designed to compare IPC with talc pleurod-
esis for the management of malignant pleural effusion.
The trial is registered on the Australian New Zealand
Clinical Trial Registry (ACTRN12611000567921). The
study is also registered on the West Australian Health
Research Management System (ID: 2019). The trial will
be conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice (GCP) and the
National Statement.
The primary end point is the total number of days
spent in hospital (for any cause of admission) from
treatment procedure to death or end of study follow-up.
The secondary research end points include:
▸ Admissions (days and number of episodes) for
pleural effusion-associated causes. This includes
admissions for management of pleural effusion, asso-
ciated symptoms, related procedures and/or their
complications.
▸ Survival and adverse events from enrolment to death
or end of follow-up.
▸ Breathlessness score and self-reported quality-of-life
scores recorded at regular intervals from enrolment
to death or end of follow-up.
▸ Health cost assessment.
▸ Need for further pleural interventions.
Setting
The study will recruit 146 patients with a malignant
pleural effusion (see below for the inclusion criteria)
requiring effusion management from the participating
centres (see online supplementary appendix 1). Patients
will be randomised to receive either IPC or pleurodesis
(ﬁgure 1).
Power calculation
In our pilot non-randomised study,17 those who chose to
have IPC (n=34) for management of their malignant
effusion spent a median of 6.5 days (IQR 3.75–13.0) in
hospital compared with 18.0 days (IQR 8.0–26.0;
p=0.002) in the talc group (n=31). The primary
response data are likely to be highly skewed, and hence
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a non-parametric test would be more appropriate. To
examine the potential beneﬁt of reduction in hospital
stay using IPC, we estimate 65 patients in each group are
needed. The study will be able (with 80% power and
α=0.05) to detect a difference of 5 or more days spent in
hospital, based on preliminary estimates of 18 days in
the pleurodesis group (from the pilot study17) and a SD
of 9.3. Allowing for a lost-to-follow-up rate of 12%, 73
patients per group will be needed, to make a total
recruitment target of 146. This is a conservative estimate
as no patient was lost to follow-up in the pilot study.
Statistical plan—missing data
In common with many clinical studies, missing data may
exist either in the form of total non-response (eg, attri-
tion due to death or patient withdrawal) or item non-
response (when some but not all the required informa-
tion is collected from the patients). We will attempt to
minimise the missing data due to item non-response.
Throughout the duration of the trial, participants will
have regular contact with the respiratory department, as
well as with the research team. The patient will be asked
to complete the forms while at clinic. This will maximise
proper and complete data collection. The research team
will document as accurately as possible the reasons for
any non-completion or missing data, thereby minimising
truly absent data. The expected dropout from patient
death has been factored into the power calculation and
is based on survival ﬁgures. The detail of the statistical
analysis will be set out in the Statistical Analysis Plan.
Participant screening and selection
Potential participants will be recruited from the respira-
tory and/or oncology clinics of the participating centres.
Patients with a known or likely malignant pleural effu-
sion that requires management to control symptoms will
be identiﬁed by the clinicians. The potential patient will
be approached about the possibility of taking part in the
study if they are at the point of requiring intervention
for the management of their malignant pleural effusion.
Figure 1 Study flow chart (IPC,
indwelling pleural catheter; CXR,
chest X-ray).
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They will be given an explanation of the study by the
doctor and then given the participant information and
consent form (PICF) to read through and ask questions
of the doctor. An informed consent will be obtained
before study enrolment. As both treatment options are
well established and approved therapies, one or the
other would be employed irrespective of whether the
patient decided to be enrolled in the study.
Individual centres will maintain a screening log of
patients including those who did not enter the study.
Inclusion criteria
1. Patients must have a symptomatic malignant pleural
effusion requiring intervention. The diagnosis may
be established by:
A. Histocytologically proven pleural malignancy or
B. Recurrent large exudative pleural effusion with
histologically proven cancer outside the thorax
and no alternative cause
2. Written informed consent
Exclusion criteria
1. Age under 18 years
2. Effusion smaller than 2 cm at maximum depth
3. Expected survival less than 3 months
4. Chylothorax
5. Previous lobectomy or pneumonectomy on the side
of the effusion
6. Previous attempted pleurodesis
7. Pleural infection
8. Total blood white cell count less than 1.0×109/L
9. Hypercapnic ventilatory failure
10. Patients who are pregnant or lactating
11. Irreversible bleeding diathesis
12. Irreversible visual impairment
13. Inability to give informed consent or comply with
the protocol
Informed consent
A doctor will conﬁrm patient eligibility prior to consent
being taken. Patients will be given the opportunity to
consider the PICF and time to ask questions prior to
written, informed consent being taken by the study
doctor.
Randomisation
Patients will be randomly assigned (1:1) to either an
indwelling ambulatory pleural catheter or talc pleurod-
esis for their malignant pleural effusion.
Randomisation will include minimisation for
1. Australasian centres versus centres outside Australasia
(Singapore and Hong Kong). This is because of
potential differences in patient ethnicity and distribu-
tion of cancer types;
2. Mesothelioma versus non-mesothelioma. This is
because median survival is signiﬁcantly longer in
mesothelioma compared with metastatic pleural
cancers.22 Also, the risk of catheter-associated
subcutaneous tumour invasion may be higher with
mesothelioma;
3. The presence versus absence of known trapped lung.
The presence of a trapped lung is likely to reduce
the likelihood of a successful pleurodesis.
To maintain allocation concealment, randomisation is
performed in real time by a web interface (Filemaker
Server Advanced, Filemaker Inc, Santa Clara, California,
USA). Initially, a minimisation programme was used so
that patients within Australia and New Zealand
(Australasia) were allocated with a probability of 0.5–0.7
favouring the treatment that would minimise differences
between groups on two key prognostic factors (meso-
thelioma and trapped lung). When Singapore was
added as a site in early 2014, stratiﬁcation by region
(Australasia vs Singapore/Hong Kong) was added to
account for any potential differences in baseline
characteristics between patient and disease cohorts. The
probability favouring the treatment that would minimise
bias was increased to 0.8 accordingly to compensate for
this added variable.23
Standard care
All patients will receive usual standard care, for example,
chemotherapy and radiotherapy, as recommended by
their attending clinicians. Patients requiring assistance
from other services, for example, the surgeons, palliative
care team or hospice will be referred when needed by
the clinical team. Co-enrolment in other clinical trials
will be discussed on an individual basis, but will be con-




Bedside talc pleurodesis is a commonly used treatment
worldwide.3 Talc is delivered as a suspension in saline via
a chest tube, which is clamped for a short time (usually
1–4 h). There are variations among most centres world-
wide in the precise details as there is no evidence-based
guideline to deﬁne the best administration protocols.24
As a pragmatic real-life study, the AMPLE trial allows each
centre to perform the talc pleurodesis as per their usual
practice, including the choice of the size of chest drain
used, timing of talc instillation and chest drain removal.
Indwelling pleural catheter
IPC has been approved by the Food and Drug
Administration (USA) since the initial safety trials in the
late 1990s.25 The catheter remains in situ as long as it is
needed, but can be removed if ﬂuid production stops, or
if otherwise clinically indicated. All patients are given an
information sheet with detailed instructions and contact
details for support. Patients with IPCs have the support
and care of the experienced community respiratory
nurse and the attending clinical team, as per standard
care. The attending clinician will decide on the details of
aftercare most suitable for individual patients, including
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drainage frequencies, personnel performing the drain-
age, etc, as well as management of any complications.
Data collection and management
Clinical data will be collected at the randomisation visit.
Patients will be asked to complete two quality-of-life
questionnaires (modiﬁed EQ-5D and visual analogue
scale (VAS) scores) at the baseline. Following the study
intervention, patients will be asked to complete a daily
VAS score for their breathlessness and one for
quality-of-life every day for the following 14 days. A modi-
ﬁed EQ-5D will also be completed by the patient on day
8 after the intervention. Follow-up visits will be under-
taken at 10–14 days, and then every 2 weeks for 8 weeks,
monthly for 6 months and every 3–12 months thereafter,
provided it is feasible. Data will be collected on hospital
admissions, details of any chemotherapy received and
any adverse events. A clinical review will be conducted
by the clinician in-charge. When patients are not, or
cannot be, seen in clinic, they will receive a phone call
from a study doctor or research nurse to enquire about
symptoms at the intervention site. They will also com-
plete the above questionnaires.
Primary outcome
The number of days spent in hospital (bed days) for any
cause for all hospital admissions following intervention,
until death or the end of the study follow-up. The
primary end point is chosen as it is the most meaningful
outcome for patients with cancer and their clinicians.
Hospital admissions will be further categorised and the
days of admissions directly attributable to the pleural
effusion and/or its treatment will be recorded as
‘effusion-related’ (a secondary end point).
Given the impossibility of blinding, hospital admis-
sions will be decided by the independent treating physi-
cians, not by the investigators, wherever possible. The
reason(s) for admission must be documented and satisfy
at least one of the following criteria:
▸ A procedure is required that cannot be performed in
the outpatient setting because of the need for >2 h of
close nursing or medical attention.
▸ A coexisting or new medical problem requires
inpatient therapy.
▸ Cancer or effusion-related symptoms cannot be
adequately controlled at home with community nursing,
general practitioner and outpatient clinic support.
The number of days spent in hospital is deﬁned as the
number of nights the patient is an inpatient at midnight.
Any hospital admission involving one or more days will
be counted towards the primary outcome. Therefore
day-case procedures including chemotherapy administra-
tion will not be included.
An independent assessor, not related to the clinical
trial, will assess the validity of the hospital admissions for
its justiﬁcation and duration. Time-to-event analysis will
be used to assess length of hospital stay (measured as
time from the study intervention until discharge) using a
competing risk model, where death is the competing risk.
Secondary outcomes
▸ Admissions (days and number of episodes) for
pleural effusion-associated causes. This includes
admissions for management of pleural effusion, asso-
ciated symptoms, related procedures and/or their
complications.
▸ Survival and adverse events from enrolment to death
or end of follow-up.
▸ Breathlessness (visual analogue) and self-reported
quality-of-life scores at regular intervals from enrol-
ment to death or end of follow-up.
▸ Health cost assessment: direct clinical costs from local
department coding data and other estimated
community-based costs will be captured from patient
data.
Figure 2 Statistical analysis
plan (IPC, indwelling pleural
catheter).
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Statistical analysis plan
All outcomes will be analysed for superiority. Superiority
analyses will be two-sided and considered statistically sig-
niﬁcant at the 5% level (ﬁgure 2). Unless otherwise
stated, all analyses will be adjusted for the minimisation
variables described above. Mean imputation will be used
during analyses to adjust for missing values of baseline
variables.
All analyses will be conducted on an intention-to-treat
and also per-protocol basis. The primary end point, that
is, total bed days for all hospital admissions will be ana-
lysed initially using a Mann-Whitney non-parametric test
to compare the two treatment arms. Subsequent sup-
porting analyses will be carried out using a negative
binomial model with adjustments made for actual length
of follow-up (accounting for death and withdrawals) and
important covariates. The total effusion-related bed days
for hospital admissions will be analysed similarly to the
primary outcome variable. Cox proportional hazards
models will be used to analyse time to death, serious
adverse events and further pleural intervention.
Summaries and frequencies of serious adverse events
will be compared between the intervention groups using
Fisher’s exact tests. VAS scores will be analysed using
linear mixed effects models, including ﬁxed effects of
time and time dependent covariates as appropriate and
random effects of individual.
Changes to the protocol after the start of the trial
The trial details documented here are consistent with
AMPLE trial protocol V.4 (date: 05/05/2014). A summary
of the trial amendments can be found in online supple-
mentary appendix 2.
ETHICS AND DISSEMINATION
The trial has been favourably reviewed by the following
committees:
▸ Sir Charles Gairdner Group Human Research Ethics
Committee (HREC) for WA Health hospitals (SCGG
2012-005);
▸ St John of God Health Care Ethics Committee for
Bunbury Hospital, WA (Ref: 670);
▸ St Vincent’s Health and Aged Care HREC for Holy
Spirit, Northside Hospital, Queensland (HREC #13/
01);
▸ South Eastern Sydney Local Health District HREC for
eastern state hospitals (HREC/13/POWH/110);
▸ Health and Disability Ethics Committee for New
Zealand hospitals (CEN/11/06/031/AM04);
▸ National Healthcare Group Domain Speciﬁc Review
Board Approval for National University Hospital,
Singapore (2013/00826);
▸ Institutional Review Board of the University Hong
Kong/Hospital Authority Hong Kong West Cluster
for Queen Mary Hospital, Hong Kong (UW14-191).
Should a protocol amendment become necessary, the
patient consent form and patient information form may
need to be revised to reﬂect the changes to the protocol.
It is the responsibility of the investigator to ensure that
an amended consent form is reviewed and has received
approval/favourable opinion from the ethics committee
and other regulatory authorities, as required by ICH
GCP and by local laws and regulations, and that it is
signed by all patients subsequently entered in the study
and those currently in the study, if affected by the
amendment (see online supplementary appendix 2).
Monitoring
Data monitoring will be completed by study staff from
the lead site. No interim analysis is planned.
Safety reporting
Data will be collected at each trial visit regarding any
adverse events and serious adverse events (as deﬁned by
ICH GCP). All serious adverse events causally related to
treatment procedures will be reported to the relevant
HREC, the lead site and the Data and Safety Monitoring
Committee (DSMC).
Data safety
Prior to patient participation in the study, written
informed consent must be obtained from each patient
(or the patient’s legally accepted representative) accord-
ing to ICH GCP and to the regulatory and legal require-
ments of the participating country. Each signature must
be personally dated by each signatory and the informed
consent and any additional patient information form
retained by the investigator as part of the study records.
A signed copy of the informed consent and any add-
itional patient information must be given to each patient
or the patient’s legally accepted representative.
The patient must be informed that his/her personal
study-related data will be used by the principal investiga-
tor in accordance with the local data protection law. The
level of disclosure must also be explained to the patient.
The patient must be informed that his/her medical
records may be examined by authorised monitors or
clinical auditors appointed by appropriate ethics com-
mittee members, and by inspectors from regulatory
authorities.
Trial monitoring and oversight
The Trial Steering Committee (TSC) will be responsible
for overseeing the progress of the trial and will meet at
regular intervals. The TSC includes an independent
chairperson, independent member, the chief investiga-
tor and the trial coordinators. It will review recommen-
dations from the DSMC through their monitoring of
adverse events and therefore determine whether or not
there is a need for early trial cessation. The committee
has a Standard Operating Procedure that deﬁnes the
terms and conditions of the group. This is to be sent out
to all named committee members.
The DSMC will ensure the safety of study participants
through the monitoring of the trial procedure, adverse
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events, serious adverse events and impact on the trial
from any relevant new literature. The committee has a
Standard Operating Procedure which deﬁnes the terms
and conditions of the group. This is to be sent out to all
named committee members.
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